EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitMetaanalyseOpen Access · CC BY-NC-ND 4.0

The prognostic value of HER2 in gastroesophageal adenocarcinoma – a meta-analysis

Kristian Egebjerg, Jan Trøst Jørgensen, Michael Charles Sachs, Morten Mau-Sørensen

Cancer Treatment and Research Communications · 2026 · 49 · 101453

DOI: 10.1016/j.ctarc.2026.101453 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Kristian Egebjerg und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. Electronic address: kristian.egebjerg.02@regionh.dk. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Danmarks Frie Forskningsfond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: HER2 amplification and overexpression are predictive markers for HER2-targeted therapies in gastroesophageal adenocarcinoma. However, unlike in breast cancer, the prognostic significance of HER2 status in this disease remains uncertain, with conflicting evidence across studies. METHODS: We conducted a systematic review and meta-analysis of studies reporting hazard ratios (HRs) for overall survival (OS) based on HER2 status, identified through PubMed, Scopus, and Web of Science. Eligible studies included HER2-positive and HER2-negative patients with gastroesophageal adenocarcinoma, using IHC and/or ISH diagnostics. Pooled HRs were calculated using random-effects models. Subgroup analyses and meta-regressions were performed by stage, treatment, and covariates. A novel statistical framework was applied to contextualize HER2's prognostic role. RESULTS: Eighty studies encompassing 30,574 patients were included. HER2 positivity was associated with poorer OS in univariate analyses for stage I-III (HR 1.29, 95% CI: 1.02-1.61) and stage I-IV disease (HR 1.58, 95% CI: 1.14-2.20), and remained significant in multivariate analyses (HR 1.46 and HR 1.52, respectively). In metastatic disease, HER2 positivity was associated with poorer survival in untreated cohorts (multivariate HR 1.37, 95% CI: 1.01-1.85; p = 0.043), but with improved survival in trastuzumab-treated cohorts in univariate analysis (HR 0.73, 95% CI: 0.61-0.88; p = 0.0007) and borderline multivariate analysis (HR 0.71, 95% CI: 0.50-1.00; p = 0.047). CONCLUSIONS: HER2 positivity was independently associated with poorer overall survival in gastroesophageal adenocarcinoma. In metastatic disease, pooled estimates differed according to trastuzumab exposure, with more favorable outcomes observed in trastuzumab-treated HER2-positive cohorts. These findings support an adverse prognostic association of HER2 positivity and further investigation of HER2-directed therapy in earlier-stage disease.

Schlagwörter

Stichwörter der Autor:innen

ERBB2Esophageal cancerGastric CancerGastroesophageal adenocarcinomaHER2PrognosticTrastuzumab

Autor:innen und Institutionen

  • Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. Electronic address: kristian.egebjerg.02@regionh.dk.
  • Medical Science, Dx-Rx Institute, Fredensborg, Denmark.
  • Department of Public Health, Copenhagen University, Copenhagen, Denmark.
  • Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

Förderung

  • Danmarks Frie Forskningsfond

Zitieren

APA

Egebjerg, K., Jørgensen, J. T., Sachs, M. C., & Mau-Sørensen, M. (2026). The prognostic value of HER2 in gastroesophageal adenocarcinoma – a meta-analysis. Cancer Treatment and Research Communications, 49, 101453. https://doi.org/10.1016/j.ctarc.2026.101453

Vancouver

Egebjerg K, Jørgensen JT, Sachs MC, Mau-Sørensen M. The prognostic value of HER2 in gastroesophageal adenocarcinoma – a meta-analysis. Cancer Treatment and Research Communications. 2026;49:101453. doi:10.1016/j.ctarc.2026.101453

BibTeX
@article{Egebjerg2026,
  author = {Egebjerg, Kristian and Jørgensen, Jan Trøst and Sachs, Michael Charles and Mau-Sørensen, Morten},
  title = {The prognostic value of HER2 in gastroesophageal adenocarcinoma – a meta-analysis},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  volume = {49},
  pages = {101453},
  doi = {10.1016/j.ctarc.2026.101453}
}
Kostenlos starten →